SCHEDULE: Madison Avenue Group Discloses 6.6% Stake in Veradigm
Beneficial Ownership Disclosure
A group of investment entities led by Eli Samaha has disclosed a 6.6% beneficial ownership stake in healthcare technology company Veradigm Inc.
Summary
- Madison Avenue International LP, Madison Avenue Partners, LP, EMAI Management, LLC, Madison Avenue GP, LLC, Caraway Jackson Investments LLC, and Eli Samaha (collectively, the "Reporting Persons") have reported beneficial ownership of 7,167,999 shares of Veradigm Inc. Common Stock.
- This aggregate amount represents approximately 6.6% of Veradigm Inc.'s outstanding Common Stock.
- The percentage is based on 108,900,000 shares of Common Stock outstanding as of September 29, 2025, as previously disclosed by Veradigm Inc.
- The Reporting Persons share both voting and dispositive power over all 7,167,999 shares.
- The shares were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of Veradigm Inc., other than activities solely in connection with a nomination under Rule 14a-11.
Sentiment
Score: 7
Explanation: StockSavvy.ai views this as a moderately positive development, as a significant stake by a group of investment entities typically signals confidence in the company's value, although the explicit mention of potential director nominations introduces a minor element of uncertainty regarding future governance.
Positives
- The disclosure of a significant 6.6% stake by a group of investment entities may signal investor confidence in Veradigm Inc.'s current valuation or future prospects.
Negatives
- No explicit negatives are detailed in this beneficial ownership disclosure.
Risks
- The Reporting Persons' certification explicitly allows for activities solely in connection with a nomination under Rule 14a-11, indicating a potential for future engagement in director elections, which could lead to governance challenges or shifts in board composition.
Future Outlook
This filing does not contain any forward-looking statements or guidance from Veradigm Inc. or the Reporting Persons regarding the company's future performance.
Management Comments
- Eli Samaha, as Manager of Madison Avenue GP, LLC, the General Partner of Madison Avenue International LP, certified that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer, other than activities solely in connection with a nomination under Rule 14a-11.
Industry Context
StockSavvy.ai notes that a significant stake by a group of investment entities in a healthcare technology company like Veradigm Inc. can draw attention to the sector, especially given the ongoing digital transformation in healthcare. Such an investment might reflect a belief in the company's long-term growth potential within the competitive health IT landscape.
Comparison to Industry Standards
- This filing is a standard disclosure of beneficial ownership, not a performance report, so direct comparison to industry financial or operational benchmarks is not applicable.
- The 6.6% stake is a substantial position, indicating a high level of conviction from the Reporting Persons, comparable to other significant institutional investments seen in mid-cap healthcare technology firms.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Potential Shareholder Engagement | The Reporting Persons have certified that their acquisition and holding of shares are not for changing or influencing control, except for activities solely in connection with a nomination under Rule 14a-11. This implies a potential for the Reporting Persons to nominate directors to Veradigm Inc.'s board. | 2026-01-29 | This could lead to increased shareholder activism or influence on board composition, potentially impacting strategic direction or management decisions, even if not aimed at outright control. |
Stakeholder Impact
- Shareholders: The disclosure of a significant stake by a group of investment entities could be perceived as a positive signal, potentially influencing market sentiment and share price. The possibility of director nominations could also lead to changes in corporate governance that may affect shareholder value.
- Management: The potential for director nominations under Rule 14a-11 suggests that current management may face increased scrutiny or pressure from this significant shareholder group.
Next Steps
- The Reporting Persons may engage in activities related to director nominations under Rule 14a-11, as certified in the filing.
Key Dates
| Date | Description |
|---|---|
| 2025-09-29 | Date as of which 108,900,000 shares of Common Stock were outstanding, used for percentage calculation. |
| 2025-09-30 | Date of Issuer's press release disclosing outstanding shares, filed as Exhibit 99.1 to Form 8-K. |
| 2026-01-22 | Date of event which requires the filing of this Schedule 13G statement. |
| 2026-01-29 | Date the Schedule 13G statement was signed and filed. |
Keywords
Veradigm Inc., VDRM, Schedule 13G, Beneficial Ownership, Institutional Investor, Healthcare Technology, Madison Avenue, Eli Samaha, Equity Stake
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.